Literature DB >> 15001327

Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections.

Carlos Hidalgo-Grass1, Mary Dan-Goor, Alexander Maly, Yoni Eran, Laura A Kwinn, Victor Nizet, Miriam Ravins, Joseph Jaffe, Amos Peyser, Allon E Moses, Emanuel Hanski.   

Abstract

BACKGROUND: Necrotising soft-tissue infections due to group A streptococcus (GAS) are rare (about 0.2 cases per 100000 people). The disease progresses rapidly, causing severe necrosis and hydrolysis of soft tissues. Histopathological analysis of necrotic tissue debrided from two patients (one with necrotising fasciitis and one with myonecrosis) showed large quantities of bacteria but no infiltrating neutrophils. We aimed to investigate whether the poor neutrophil chemotaxis was linked with the ability of group A streptococcus (GAS) to degrade host chemokines.
METHODS: We did RT-PCR, ELISA, and dot-blot assays to establish whether GAS induces synthesis of interleukin 8 mRNA, but subsequently degrades the released chemokine protein. Class-specific protease inhibitors were used to characterise the protease that degraded the chemokine. We used a mouse model of human soft-tissue infections to investigate the pathogenic relevance of GAS chemokine degradation, and to test the therapeutic effect of a GAS pheromone peptide (SilCR) that downregulates activity of chemokine protease.
FINDINGS: The only isolates from the necrotic tissue were two beta-haemolytic GAS strains of an M14 serotype. A trypsin-like protease released by these strains degraded human interleukin 8 and its mouse homologue MIP2. When innoculated subcutaneously in mice, these strains produced a fatal necrotic soft-tissue infection that had reduced neutrophil recruitment to the site of injection. The M14 GAS strains have a missense mutation in the start codon of silCR, which encodes a predicted 17 aminoacid pheromone peptide, SilCR. Growth of the M14 strain in the presence of SilCR abrogated chemokine proteolysis. When SilCR was injected together with the bacteria, abundant neutrophils were recruited to the site of infection, bacteria were cleared without systemic spread, and the mice survived. The therapeutic effect of SilCR was also obtained in mice challenged with M1 and M3 GAS strains, a leading cause of invasive infections.
INTERPRETATION: The unusual reduction in neutrophils in necrotic tissue of people with GAS soft-tissue infections is partly caused by a GAS protease that degrades interleukin 8. In mice, degradation can be controlled by administration of SilCR, which downregulates GAS chemokine protease activity. This downregulation increases neutrophil migration to the site of infection, preventing bacterial spread and development of a fulminant lethal systemic infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001327     DOI: 10.1016/S0140-6736(04)15643-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  51 in total

1.  A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues.

Authors:  Carlos Hidalgo-Grass; Inbal Mishalian; Mary Dan-Goor; Ilia Belotserkovsky; Yoni Eran; Victor Nizet; Amnon Peled; Emanuel Hanski
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

2.  Molecular diagnosis of necrotizing fasciitis by 16S rRNA gene sequencing and superantigen gene detection.

Authors:  Kenneth L Muldrew; Jean F Simpson; Charles W Stratton; Yi-Wei Tang
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

3.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

4.  Molecular epidemiology of the sil streptococcal invasive locus in group A streptococci causing invasive infections in French children.

Authors:  Philippe Bidet; Céline Courroux; Christophe Salgueiro; Agnès Carol; Patricia Mariani-Kurkdjian; Stéphane Bonacorsi; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

5.  SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages.

Authors:  Hilary A Phelps; Melody N Neely
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

6.  An extracellular bacterial pathogen modulates host metabolism to regulate its own sensing and proliferation.

Authors:  Moshe Baruch; Ilia Belotserkovsky; Baruch B Hertzog; Miriam Ravins; Eran Dov; Kevin S McIver; Yoann S Le Breton; Yiting Zhou; Catherine Youting Cheng; Catherine Youting Chen; Emanuel Hanski
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

7.  Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors.

Authors:  Mariko Honda-Ogawa; Taiji Ogawa; Yutaka Terao; Tomoko Sumitomo; Masanobu Nakata; Kazunori Ikebe; Yoshinobu Maeda; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

8.  Host Genetic Variations and Sex Differences Potentiate Predisposition, Severity, and Outcomes of Group A Streptococcus-Mediated Necrotizing Soft Tissue Infections.

Authors:  Karthickeyan Chella Krishnan; Santhosh Mukundan; Jeyashree Alagarsamy; Donna Laturnus; Malak Kotb
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

9.  SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines.

Authors:  Arne Egesten; Anders I Olin; Helena M Linge; Manisha Yadav; Matthias Mörgelin; Anna Karlsson; Mattias Collin
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

10.  Functional analysis of the quorum-sensing streptococcal invasion locus (sil).

Authors:  Ilia Belotserkovsky; Moshe Baruch; Asaf Peer; Eran Dov; Miriam Ravins; Inbal Mishalian; Merav Persky; Yoav Smith; Emanuel Hanski
Journal:  PLoS Pathog       Date:  2009-11-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.